Most-Favored-Nation (MFN) Pricing — Lanton Law Blog

Lanton Law Moderates Most Favored Nation Panel for MJH Life Sciences

Lanton Law was honored to be selected as a moderator for the MJH Life Sciences panel titled ““Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform.”

healthcare, life sciences, Medicare Part B, Most Favored Nation, pharmaceuticals, prescription drug costsRon LantonOctober 12, 2025MFN, Most-Favored-Nation (MFN) Pricing, Pfizer, Drug Price, Medicare Part B, Inflation Reduction Act, IRA, insurance, healthcare, pharmaceutical, PhRMA

Lanton Law Interviewed by Pharmacy Times Over Prescription Drug Price Executive Order

Lanton Law was quoted in Pharmacy Times’ article titled “President Trump Signs Executive Order Aiming to Lower Prescription Drug Costs by Up to 90%.”

healthcare, pharmaceuticals, pharmacy benefit manager, prescription drug costs, PhRMARon LantonMay 14, 2025prescription drug prices, Executive Order, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients, Most-Favored-Nation (MFN) Pricing, MFN, healthcare, prescription, pharmaceutical, drug manufacturer

Understanding the 2025 Executive Order on Most-Favored-Nation Drug Pricing: Implications for Healthcare Stakeholders

On May 12, 2025, President Trump signed an executive order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," aiming to align U.S. prescription drug prices with the lowest prices paid by other developed nations.